AUSTIN, Texas / Sep 02, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025.
Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Event Details:
Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email This email address is being protected from spambots. You need JavaScript enabled to view it.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies—such as its LENSai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research.
For more information, visit www.ipatherapeutics.com.
| Last Trade: | US$1.93 |
| Daily Volume: | 0 |
| Market Cap: | US$89.070M |
December 15, 2025 October 15, 2025 September 22, 2025 September 15, 2025 August 27, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
